The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Commentary|Articles|October 29, 2025
Precision Strategies and Targeted Combinations in GU Oncology: Expert Insights From ESMO 2025
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.
Advertisement
Advertisement
Precision medicine, biomarker-driven treatment selection, and next-generation targeted combinations took center stage in genitourinary (GU) oncology at the
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.
Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.
Adding durvalumab to BCG induction and maintenance reduced high-risk recurrences in patients with papillary-only bladder tumors in POTOMAC.
Perioperative enfortumab vedotin plus pembrolizumab showed no clinically meaningful HRQOL detriment in cisplatin-eligible MIBC.
The claudin 6–targeted antibody-drug conjugate ixotatug vedotin showed antitumor activity in recurrent germ cell tumors, including after transplant.
Advertisement
Advertisement